Genitope Corp.
This article was originally published in Start Up
Executive Summary
Genitope is using a novel gene expression technology in cancer immunotherapy. Starting with a tumor sample, it produces patient-specific idiotype antibodies which target B cell tumors and stimulate an immune response. The strategy is equivalent to that used in over a decade of clinical studies by Ron Levy of Stanford University, who encouraged Genitope founder Dan Denney to start the company.
You may also be interested in...
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.